Abstract:Botulinum neurotoxin type A (BoNT/A) is a potent metalloprotease that acts primarily by specifically cleavage of presynaptic synaptosomal-associated 25 kDa (SNAP-25), consequently blocking the release of neurotransmitters such as acetylcholine (ACh) at the neuromuscular junction and autonomic innervations of glands and smooth muscles. Long-term and repeated application of BoNT/A is the therapeutic basis for diseases such as dystonia, muscle spasms and so on. Accumulating evidence suggested that toxin can be retrograde axonal transported to the central nervous system (CNS) or indirectly affect somatosensory-motor cortical excitability and neuronal plasticity induced by altered proprioceptive signals from the periphery. However, the central effects of repeated BoNT/A injection on cognitive function as well as basal forebrain- hippocampal cholinergic signaling pathway remain unclear.Here, we investigated the long-term effect on cognitive performance through repeated doses of 10 U/kg BoNT/A facial injections in adult C57BL/6 mice. Using a range of behavioral paradigms including open field task, novel object recognition task, Y-maze and Morris water maze, we found that repeated facial application of BoNT/A did not impair motor coordination and cognitive performance. Even mice with repeatedly administered BoNT/A displayed enhanced working memory in Y-maze task; whereas the single BoNT/A treatment failed to improve the memory-related behaviors. Furthermore, the expression of choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) proteins in the hippocampus significantly increased following multiple BoNT/A injections. An immunofluorescence analysis demonstrated that the number of basal forebrain cholinergic neurons increased as the doses were increased. However, no changes in cholinergic levels were observed in the single BoNT/A-injection group. This study could inform safety considerations linked to BoNT/A in the clinic and contribute to the development of its widespread application in diverse diseases.

Recombinant luminal domain of human synaptotagmin II in combination with gangliosides inhibits the toxicity of botulinum neurotoxins in mice.

A New Neutralizing Antibody Against Botulinum Neurotoxin B Recognizes the Protein Receptor Binding Sites for Synaptotagmins II.

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

The Behavioural Effects and Sept-Hippocampal Cholinergic Activity Changes Caused by Repeated Bont/A Injection on Facial Muscle in Adolescent Mice

Discovery of a Potent Botulinum Neurotoxin A Inhibitor ZM299 with Effective Protections in Botulism Mice

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin

Expression, purification and application of a recombinant, membrane permeating version of the light chain of botulinum toxin B

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E

Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication Studies

Tetanus toxin and botulinum neurotoxin–derived fusion molecules are effective bivalent vaccines

Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin

Tirbanibulin (KX2‐391) analog KX2‐361 inhibits botulinum neurotoxin serotype A mediated SNAP‐25 cleavage in pre‐ and post‐intoxication models in cells

A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling

Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice

A novel conotoxin from Conus striatus, μ-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels

Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2